https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=31320490&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31320490</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1438</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</Title><ISOAbbreviation>Int J Gynecol Cancer</ISOAbbreviation></Journal><ArticleTitle>Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment.</ArticleTitle><Pagination><StartPage>1121</StartPage><EndPage>1125</EndPage><MedlinePgn>1121-1125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/ijgc-2019-000387</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Sentinel lymph node (SLN) mapping is increasingly being used in the treatment of apparent early-stage endometrial cancer. The aim of this study was to evaluate whether three tracers (blue dye, indocyanine green (ICG), and technetium-99 (Tc99)) performed better than two (ICG and Tc99).</AbstractText><AbstractText Label="STUDY DESIGN">Prospective study of all consecutive patients (n=163) diagnosed with clinical early-stage endometrial cancer from 2015 to 2017. All patients were randomly assigned to receive a mixture of ICG and Tc99 with or without blue dye. Subgroup analysis for detection rates was performed for each group (double versus triple tracer).</AbstractText><AbstractText Label="RESULTS">One hundred and fifty-seven patients met the inclusion criteria. Eighty patients received ICG and Tc99 with unilateral and bilateral SLN detection rates of 97.5% and 81.3%, respectively. Seventy-seven patients received all three tracers with unilateral and bilateral detection rates of 93.5% and 80.5%, respectively. Only one patient in the triple tracer group was detected by blue dye alone. No significant differences were noticed in unilateral or bilateral detection rates between the two groups, nor in the detection of lymph node metastasis.</AbstractText><AbstractText Label="CONCLUSION">The addition of blue dye to ICG and Tc99 did not demonstrate any improvement in SLN detection.</AbstractText><CopyrightInformation>&#xa9; IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kessous</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology; Faculty of Health Sciences, Soroka University Medical Center; Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>How</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abitbol</LastName><ForeName>Jeremie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzhakkal</LastName><ForeName>Sanam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogan</LastName><ForeName>Liron</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasmeen</LastName><ForeName>Amber</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotlieb</LastName><ForeName>Walter H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada walter.gotlieb@mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Susie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Jewish General Hospital - McGill University Faculty of Medicine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Gynecol Cancer</MedlineTA><NlmUniqueID>9111626</NlmUniqueID><ISSNLinking>1048-891X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012394">Rosaniline Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000615519">Technetium-99</NameOfSubstance></Chemical><Chemical><RegistryNumber>7440-26-8</RegistryNumber><NameOfSubstance UI="D013667">Technetium</NameOfSubstance></Chemical><Chemical><RegistryNumber>FH1929ICIT</RegistryNumber><NameOfSubstance UI="C008769">sulfan blue</NameOfSubstance></Chemical><Chemical><RegistryNumber>IX6J1063HV</RegistryNumber><NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="Y">Coloring Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012394" MajorTopicYN="N">Rosaniline Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071036" MajorTopicYN="N">Sentinel Lymph Node</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013667" MajorTopicYN="N">Technetium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blue dye</Keyword><Keyword MajorTopicYN="N">endometrial cancer</Keyword><Keyword MajorTopicYN="N">indocyanine green</Keyword><Keyword MajorTopicYN="N">sentinel lymph node mapping</Keyword><Keyword MajorTopicYN="N">technetium</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31320490</ArticleId><ArticleId IdType="doi">10.1136/ijgc-2019-000387</ArticleId><ArticleId IdType="pii">ijgc-2019-000387</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>